🚨 这是一种能够改变复发性 SCLC 讨论的生存信号。
@OncoAlert
在 #ESMO26 上，来自 III 期 DeLLphi-304 研究的延长随访进一步支持了在一线铂类化疗后使用 tarlatamab 的依据。
🫁 n=509 | 中位随访 23 个月
➡️ 中位 OS：13.6 对 8.4 个月
HR 0.62 (0.51–0.76)
➡️ 18 个月 OS：42% 对 24%
➡️ 在基线有脑转移的患者中：
OS HR 0.52 (0.38–0.70)
重要的是：
⚠️ ≥3 级 TRAE：28% 对 63%（化疗组）
🎯 为何这很重要：在一种历史上难以获得持久二线获益的疾病中，tarlatamab 同时带来了有意义的生存改善和更优的高级别毒性概况。
对我来说，脑转移亚组尤为引人注目，值得在我们明确 DLL3 靶向治疗在治疗路径中的定位时给予密切关注。
出色的工作来自 @charlesrudin @g_mountzios @cbcbc1971 @JulienMazieres @teekayowo @LuisPaz_Ares 以及 DeLLphi-304 研究者们。
通知 @christine_lovly @GlopesMd @DrSanjayPopat @StephenVLiu @jillfeldman4 @UOzkerim @DrMirallas @MartinReck2 @CharuAggarwalMD @peters_solange
#OncoAlert #ESMO26 #LungCancer #SCLC #Tarlatamab #DLL3 #Immunotherapy
220 浏览 · 3 赞 · 2 转发 · 0 回复
OncoAlert 4Sight Abstracts to be Presented at #ESMO26 Tarlatamab in Previously Treated SCLC: Extended Follow-Up of Overall Survival From the Phase 3 DeLLphi-304 Trial @charlesrudin @g_mountzios @cbcbc1971 @JulienMazieres @teekayowo @LuisPaz_Ares 🫁 Phase 3 (n=509): tarlatamab vs chemotherapy (topotecan, lurbinectedin or amrubicin) in SCLC after first-line platinum-based chemotherapy. Primary endpoint: OS; median follow-up 23 mo. ➡️ Median OS 13.6 vs 8.4 mo; HR 0.62 (0.51–0.76); 18-mo OS 42% vs 24% ➡️ Baseline brain metastases subgroup: OS HR 0.52 (0.38–0.70) ➡️ Grade ≥3 TRAEs 28% vs 63% ✅ Durable survival benefit with a manageable safety profile and no new safety signals, reinforcing tarlatamab as standard of care after first-line platinum-based chemotherapy. #LungCancer #SCLC 🎙️ Charles Rudin 👥 Giannis Mountzios · Longhua Sun · Byoung Chul Cho · Umut Demirci · Sofia Baka · Mahmut Gümüş · Antonio Lugini · Bo Zhu · Yan Yu · Ippokratis Korantzis · Ji-Youn Han · Tudor-Eliade Ciuleanu · Myung-Ju Ahn · Pedro Rocha · Julien Mazières · Sally Lau · Martin Schuler · Fiona Blackhall · Tatsuya Yoshida · Taofeek Owonikoko · Luis Paz-Ares · Tony Jiang · Ali Hamidi · Diana Gauto · Gonzalo Recondo (4Sight Made from Abstracts publicly available at the ESMO website) Pinging our faculty @christine_lovly, @GlopesMd, @DrSanjayPopat, @StephenVLiu, @jillfeldman4, @UOzkerim, @DrMirallas, @MartinReck2 , @bmassutis @UmbertoMalapel1 , @CharuAggarwalMD @peters_solange, @HenningWillers, @HHorinouchi, @BRicciutiMD, @PercyLeeMD, @bensolomon1, @Latinamd, @DrJNaidoo, @barlesi, @VanitaNoronha, @ChristianRolfo @Tony_Calles @s_couraud @marinagarassino @g_mountzios @BairdAM @barlesi @JFreemanDaily @Piuchagarrido @PercyLeeMD @bensolomon1 @VanitaNoronha @alexdrilon @JordiRemon @JulienMazieres @TerriConneran @HenningWillers在 X 查看被引用的帖子
来源：Dra. María Natalia Gandur Quiroga · x.com